Experimental drug combo takes on recurrent glioblastoma

NCT ID NCT06410248

Recruiting now Disease control Sponsor: Northwestern University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests two drugs—triapine and temozolomide—together in people whose glioblastoma has returned. The goal is to find the safest dose and see how well patients tolerate the combination. About 30 adults with recurrent grade 2-4 glioma will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: triapine and temozolomide
What this could lead to: If this works, it could point toward a new combination treatment for recurrent glioblastoma, a brain cancer with few options.
What could go wrong: This is a very early phase 1 trial with only 30 people. The main goal is safety and dosing, not yet proof of effectiveness. Side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA, IDH-WILDTYPE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma grade II glioma grade III glioma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT GLIOBLASTOMA, IDH-WILDTYPE RECURRENT WHO GRADE 2 GLIOMA RECURRENT WHO GRADE 3 GLIOMA RECURRENT WHO GRADE 4 GLIOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Northwestern University
RECRUITING

Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.